

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 28, 2025

PE anti-human CD44

RRID:AB_2076578

Type: Antibody

Proper Citation

(BioLegend Cat# 338808, RRID:AB_2076578)

Antibody Information

URL: http://antibodyregistry.org/AB_2076578

Proper Citation: (BioLegend Cat# 338808, RRID:AB_2076578)

Target Antigen: CD44

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE anti-human CD44

Description: This monoclonal targets CD44

Target Organism: human

Clone ID: Clone BJ18

Antibody ID: AB_2076578

Vendor: BioLegend

Catalog Number: 338808

Alternative Catalog Numbers: 338807

Record Creation Time: 20231110T050702+0000

Record Last Update: 20241115T023803+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-human CD44.

No alerts have been found for PE anti-human CD44.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Poch T, et al. (2024) Intergenic risk variant rs56258221 skews the fate of naive CD4+ T cells via miR4464-BACH2 interplay in primary sclerosing cholangitis. Cell reports. Medicine, 5(7), 101620.

Ross NT, et al. (2020) CPSF3-dependent pre-mRNA processing as a druggable node in AML and Ewing's sarcoma. Nature chemical biology, 16(1), 50.

Jiang L, et al. (2020) Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy. Cell, 183(5), 1219.